Hasenkamp, Justin

[["dc.bibliographiccitation.firstpage","2438"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","2447"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Doehner, Hartmut"],["dc.contributor.author","Ritgen, Matthias"],["dc.contributor.author","Boettcher, Sebastian"],["dc.contributor.author","Busch, Raymonde"],["dc.contributor.author","Dietrich, Sascha"],["dc.contributor.author","Bunjes, Donald W."],["dc.contributor.author","Cohen, Sandra"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Hegenbart, Ute"],["dc.contributor.author","Beelen, Dietrich"],["dc.contributor.author","Zeis, Matthias"],["dc.contributor.author","Stadler, Michael"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Uharek, Lutz"],["dc.contributor.author","Scheid, Christof"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Zenz, Thorsten"],["dc.contributor.author","Winkler, Dirk"],["dc.contributor.author","Hallek, Michael"],["dc.contributor.author","Kneba, Michael"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Stilgenbauer, Stephan"],["dc.date.accessioned","2018-11-07T08:38:06Z"],["dc.date.available","2018-11-07T08:38:06Z"],["dc.date.issued","2010"],["dc.description.abstract","The purpose of this prospective multicenter phase 2 trial was to investigate the long-term outcome of reduced-intensity conditioning allogeneic stem cell transplantation (alloSCT) in patients with poor-risk chronic lymphocytic leukemia. Conditioning was fludarabine/cyclophosphamide-based. Longitudinal quantitative monitoring of minimal residual disease (MRD) was performed centrally by MRD-flow or real-time quantitative polymerase chain reaction. One hundred eligible patients were enrolled, and 90 patients proceeded to alloSCT. With a median follow-up of 46 months (7-102 months), 4-year nonrelapse mortality, event-free survival (EFS) and overall survival (OS) were 23%, 42%, and 65%, respectively. Of 52 patients with MRD monitoring available, 27 (52%) were alive and MRD negative at 12 months after transplant. Four-year EFS of this subset was 89% with all event-free patients except for 2 being MRD negative at the most recent assessment. EFS was similar for all genetic subsets, including 17p deletion (17p-). In multivariate analyses, uncontrolled disease at alloSCT and in vivo T-cell depletion with alemtuzumab, but not 17p-, previous purine analogue refractoriness, or donor source (human leukocyte antigen-identical siblings or unrelated donors) had an adverse impact on EFS and OS. In conclusion, alloSCT for poor-risk chronic lymphocytic leukemia can result in long-term MRD-negative survival in up to one-half of the patients independent of the underlying genomic risk profile. This trial is registered at http://clinicaltrials.gov as NCT00281983. (Blood. 2010;116(14):2438-2447)"],["dc.description.sponsorship","Roche; Novartis; Bayer; Amgen; Celgene; Glaxo Smith-Kline"],["dc.identifier.doi","10.1182/blood-2010-03-275420"],["dc.identifier.isi","000282645900010"],["dc.identifier.pmid","20595516"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18693"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","0006-4971"],["dc.title","Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","110"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Wulf, Gerald G."],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T10:52:41Z"],["dc.date.available","2018-11-07T10:52:41Z"],["dc.date.issued","2007"],["dc.format.extent","894A"],["dc.identifier.isi","000251100804080"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49168"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","49th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","Atlanta, GA"],["dc.relation.issn","0006-4971"],["dc.title","Intermediate intensity conditioning followed by allogeneic peripheral blood stem cell transplantion for treatment of high risk relapse of aggressive lymphoma. Interim analysis of the DSHNHL R3 study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","757"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","The Lancet Oncology"],["dc.bibliographiccitation.lastpage","766"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Silling, Gerda"],["dc.contributor.author","Wilhelm, Christian"],["dc.contributor.author","Zeis, Matthias"],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2021-06-01T10:50:22Z"],["dc.date.available","2021-06-01T10:50:22Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1016/S1470-2045(14)70161-5"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86631"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","1470-2045"],["dc.title","Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","391"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","397"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Nickelsen, M."],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Claviez, Alexander"],["dc.contributor.author","Hasenkamp, J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T10:45:48Z"],["dc.date.available","2018-11-07T10:45:48Z"],["dc.date.issued","2004"],["dc.description.abstract","In patients with poor-risk relapse of aggressive lymphoma, reduced-intensity conditioning followed by allogeneic PBSCT may have its limitations because of rapid regrowth of the tumor. We tried to address this problem by intermediate-intensity conditioning followed by allogeneic SCT. A total of 21 patients received fludarabine, busulfan and cyclophosphamide prior to allogeneic SCT. In the first 10 patients, GVHD prophylaxis by CD34+ selection of the grafts was employed (group I). The next 11 patients received nonmanipulated grafts and mycophenolat mofetil plus cyclosporinA (group II). In group I, no GVHD was observed. In contrast, patients in group II had a significant risk of acute GVHD (aGVHD) (six patients with grade II-IV acute GVHD). However, in group I, all surviving patients progressed within 9 months. In contrast, eight of nine surviving patients of group II remain in remission after a median observation time of 10.5 months (range 4-22 months). Survival differed significantly between the groups (P = 0.004). Multivariate analysis identified intensive GVHD prophylaxis as important risk factor for survival. These results support the existence of a clinically relevant GVL effect in aggressive lymphoma. T-cell depletion (or CD34 selection) of grafts is not recommended in patients with poor-risk aggressive NHL."],["dc.identifier.doi","10.1038/sj.bmt.1704600"],["dc.identifier.isi","000223351200002"],["dc.identifier.pmid","15273707"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47591"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0268-3369"],["dc.title","Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","341"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","348"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Borgerding, Andrea"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Glass, Bertram"],["dc.date.accessioned","2018-11-07T08:44:18Z"],["dc.date.available","2018-11-07T08:44:18Z"],["dc.date.issued","2010"],["dc.description.abstract","Natural killer (NK) cells contribute to the graft-versus-leukemia effect after allogeneic stem cell transplantation. However, the efficacy of NK cell-mediated tumor cell lysis is limited due to target cell resistance, and target cell-induced apoptosis (TiA) was proposed to contribute to differences in susceptibility to NK cells. Here we analyzed the effects of target cells on the apoptosis of cytokine-activated NK cells in vitro. We found no association of target cell susceptibility and TiA of NK cells in an array of human and murine target-effector cell combinations. Incubation of NK cells with caspase inhibitors blocked TiA incompletely, indicating that TiA is partly based on caspase-independent mechanisms. Modulating NK cell susceptibility against TiA by caspase inhibition did not influence cytotoxic efficacy. Furthermore, we found cytotoxic potential of NK cells to be markedly decreased following first target cell contact. Exhaustion of NK cell activity by first target cell contact was, however, not mediated by TiA. In addition, we found no relevant TiA by lymphoma cell lines against activated murine NK cells. We conclude that TiA represents only a minor factor of target cell resistance against NK cell-mediated cytolysis."],["dc.description.sponsorship","Deutsche Krebshilfe"],["dc.identifier.doi","10.1007/s00277-009-0844-1"],["dc.identifier.isi","000274685400002"],["dc.identifier.pmid","19823823"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4146"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20165"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Silling, Gerda"],["dc.contributor.author","Wilhelm, Christian"],["dc.contributor.author","Zeis, Matthias"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T09:10:20Z"],["dc.date.available","2018-11-07T09:10:20Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009803810"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26463"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","0732-183X"],["dc.title","High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","877"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","884"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Wilhelm, Christian"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Glass, Bertram"],["dc.date.accessioned","2020-12-10T18:09:41Z"],["dc.date.available","2020-12-10T18:09:41Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1038/s41409-018-0360-9"],["dc.identifier.eissn","1476-5365"],["dc.identifier.issn","0268-3369"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73726"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","22"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","114"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T11:21:57Z"],["dc.date.available","2018-11-07T11:21:57Z"],["dc.date.issued","2009"],["dc.format.extent","1312"],["dc.identifier.isi","000272725804044"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55894"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","51st Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","New Orleans, LA"],["dc.relation.issn","0006-4971"],["dc.title","Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Shumilov, Evgenii; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Aperdannier, Lena; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Schmidt, Nicole; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Szuszies, Christoph; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Neesse, Albrecht; 3Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; albrecht.neesse@med.uni-goettingen.de"],["dc.contributor.affiliation","Hoffknecht, Petra; 4Department of Thorax Oncology, Franziskus-Hospital Harderberg, Niels-Stensen-Kliniken, 49124 Georgsmarienhütte, Germany; petra.hoffknecht@niels-stensen-kliniken.de"],["dc.contributor.affiliation","Khandanpour, Cyrus; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Mikesch, Jan-Henrik; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Stelljes, Matthias; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Boeckel, Göran Ramin; 6Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Münster, Germany; goeranramin.boeckel@ukmuenster.de (G.R.B.); phil-robin.tepasse@ukmuenster.de (P.-R.T.)"],["dc.contributor.affiliation","Tepasse, Phil-Robin; 6Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Münster, Germany; goeranramin.boeckel@ukmuenster.de (G.R.B.); phil-robin.tepasse@ukmuenster.de (P.-R.T.)"],["dc.contributor.affiliation","Reitnauer, Lea; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Koch, Raphael; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Hasenkamp, Justin; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Bacher, Ulrike; 8Central Hematology Laboratory, Department of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; veraulrike.bacher@insel.ch"],["dc.contributor.affiliation","Scheithauer, Simone; 9Department of Infection Control and Infectious Diseases, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; simone.scheithauer@med.uni-goettingen.de"],["dc.contributor.affiliation","Trümper, Lorenz; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Schmitz, Norbert; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Wulf, Gerald; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Kerkhoff, Andrea; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Lenz, Georg; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Krekeler, Carolin; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Bleckmann, Annalen; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Aperdannier, Lena"],["dc.contributor.author","Schmidt, Nicole"],["dc.contributor.author","Szuszies, Christoph"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Hoffknecht, Petra"],["dc.contributor.author","Khandanpour, Cyrus"],["dc.contributor.author","Mikesch, Jan-Henrik"],["dc.contributor.author","Stelljes, Matthias"],["dc.contributor.author","Boeckel, Göran Ramin"],["dc.contributor.author","Tepasse, Phil-Robin"],["dc.contributor.author","Reitnauer, Lea"],["dc.contributor.author","Koch, Raphael"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Scheithauer, Simone"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Kerkhoff, Andrea"],["dc.contributor.author","Lenz, Georg"],["dc.contributor.author","Krekeler, Carolin"],["dc.contributor.author","Bleckmann, Annalen"],["dc.date.accessioned","2022-08-03T14:40:37Z"],["dc.date.available","2022-08-03T14:40:37Z"],["dc.date.issued","2022-07-31"],["dc.date.updated","2022-08-03T12:15:44Z"],["dc.description.abstract","This study investigated SARS-CoV-2 infections and their impact on cancer in COVID-19 vaccinated (n = 49) and non-vaccinated (n = 84) cancer patients. A mild course of COVID-19 was documented more frequently in vaccinated cancer patients (49% vs. 29%), while the incidence of severe and critical courses occurred in approximately one-half of the non-vaccinated patients (22% vs. 42%). In comparison to non-vaccinated patients, admissions to intermediate and intensive care units and the need for non-invasive and invasive respiratory support were reduced by 71% and 50% among vaccinated patients. The median length of hospital stay was 11 days for non-vaccinated and 5 days for vaccinated patients. COVID-19 mortality was reduced by 83% in vaccinated patients. Finally, the median time from SARS-CoV-2 infection to restarting cancer therapy was 12 and 26 days among vaccinated and non-vaccinated groups, respectively. Our results provide evidence for the significant benefits of COVID-19 vaccines for cancer patients.\r\n \r\n \r\n Abstract\r\n COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer patients between the pre- and post-vaccine era. We analyzed SARS-CoV-2 infections and their impact on cancer in COVID-19 vaccinated and non-vaccinated patients from three German cancer centers. Overall, 133 patients with SARS-CoV-2 were enrolled in pre- and post-vaccine eras: 84 non-vaccinated and 49 vaccinated, respectively. A mild course of COVID-19 was documented more frequently in vaccinated patients (49% vs. 29%), while the frequency of severe and critical courses occurred in approximately one-half of the non-vaccinated patients (22% vs. 42%, p = 0.023). Particularly, patients with hematologic neoplasms benefited from vaccination in this context (p = 0.031). Admissions to intermediate- and intensive-care units and the necessity of non-invasive and invasive respiratory support were reduced by 71% and 50% among vaccinated patients, respectively. The median length of admission was 11 days for non-vaccinated and 5 days for vaccinated patients (p = 0.002). COVID-19 mortality was reduced by 83% in vaccinated patients (p = 0.046). Finally, the median time from SARS-CoV-2 infection to restarting cancer therapy was 12 and 26 days among vaccinated and non-vaccinated groups, respectively (p = 0.002). Although this study does not have enough power to perform multivariate analyses to account for confounders, it provides data on COVID-19 in non-vaccinated and vaccinated cancer patients and illustrates the potential benefits of COVID-19 vaccines for these patients."],["dc.identifier.doi","10.3390/cancers14153746"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112610"],["dc.language.iso","en"],["dc.relation.eissn","2072-6694"],["dc.rights","CC BY 4.0"],["dc.title","Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","689"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","690"],["dc.bibliographiccitation.volume","112"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Nickelsen, Maike"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T11:09:03Z"],["dc.date.available","2018-11-07T11:09:03Z"],["dc.date.issued","2008"],["dc.identifier.isi","000262104702307"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52925"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","50th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","0006-4971"],["dc.title","Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]